Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma

We retrospectively compared outcomes of patients with relapsed/refractory non-Hodgkin lymphoma (NHL) who underwent stem cell transplantation (SCT) with stable disease or better following a novel combination of lenalidomide and rituximab (LR) treatment and did not undergo SCT in a phase I/II clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Qingqing, Chen, Yiming, Zou, Dehui, Zhang, Liang, Badillo, Maria, Zhou, Shouhao, Lopez, Elyse, Jiang, Wenqi, Huang, Huiqiang, Lin, Tongyu, Romaguera, Jorge, Wang, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202129/
https://www.ncbi.nlm.nih.gov/pubmed/25228589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202129/
https://www.ncbi.nlm.nih.gov/pubmed/25228589

Ejemplares similares